Cardinal Health, Inc. - 10-K Summary (Fiscal Year Ended June 30, 2000)
Business Context and Reporting Period
This Annual Report on Form 10-K covers the fiscal year ended June 30, 2000. Cardinal Health, Inc. is a leading provider of products and services to healthcare providers and manufacturers. The company operates through four primary segments: Pharmaceutical Distribution and Provider Services, Medical-Surgical Products and Services, Pharmaceutical Technologies and Services, and Automation and Information Services. The company is headquartered in Dublin, Ohio, and employs approximately 42,200 people globally.
Key Financial Metrics
| Metric (in millions, except per share) | Fiscal 2000 | Fiscal 1999 |
|---|---|---|
| Total Revenue | $29,870.6 | $25,111.5 |
| Operating Revenue | $25,246.9 | $21,558.5 |
| Net Earnings | $679.7 | $481.0 |
| Diluted Earnings Per Share | $2.39 | $1.68 |
| Gross Margin % (of Operating Revenue) | 11.4% | 12.2% |
| Operating Earnings | $1,195.0 | $899.5 |
| Net Cash Provided by Operating Activities | $638.2 | $377.6 |
| Total Assets | $10,264.9 | $8,404.5 |
| Long-Term Obligations | $1,485.8 | $1,223.9 |
| Shareholders' Equity | $3,981.2 | $3,569.6 |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 19% to $29.9 billion, driven by a 17% increase in operating revenue. Growth was primarily due to increased volume and pharmaceutical price increases from existing customers, alongside new customer acquisitions.
- Profitability: Net earnings rose 41% to $679.7 million. However, gross margin percentage declined from 12.2% to 11.4%, attributed to a higher mix of lower-margin pharmaceutical distribution business (which accounted for 75% of operating revenue in 2000 vs. 72% in 1999).
- Special Charges: The company incurred $64.7 million in merger-related costs in fiscal 2000, compared to $146.6 million in fiscal 1999. These charges reduced net earnings by $49.8 million (net of tax) in 2000.
- Liquidity: Working capital increased to $2.6 billion from $2.3 billion. Cash and equivalents grew significantly to $504.6 million from $185.4 million, supported by strong operating cash flows.
Guidance, Outlook, and Risks
- Outlook: Management anticipates continued growth through cross-selling opportunities and expansion into service areas that complement core distribution. The company expects to incur an additional $69.4 million in merger-related integration costs in future periods.
- Subsequent Acquisitions: Post-fiscal year end, the company completed the purchase of Bergen Brunswig Medical Corporation ($180 million), a facility and technology rights from Advanced Polymer Systems ($25 million), and Rexam Healthcare Packaging operations ($32.5 million).
- Key Risks:
- Customer Concentration: The two largest customers accounted for 12% and 14% of operating revenue in 2000. One customer accounted for 52% of bulk deliveries.
- Legal Proceedings: The company faces ongoing litigation regarding natural rubber latex gloves (approx. 533 lawsuits) assumed from the Allegiance acquisition. While insurance is expected to cover a substantial portion, the total potential loss is currently unestimable.
- Regulatory Environment: Operations are subject to extensive regulation by the FDA, DEA, and state boards regarding drug distribution, manufacturing, and healthcare fraud/abuse laws.
Investor Verification Checklist
- Verify the impact of the 11.4% gross margin decline on future profitability as the low-margin distribution segment continues to grow.
- Review the status of the latex glove litigation and the adequacy of insurance coverage for the 533 pending lawsuits.
- Assess the integration progress and cost realization of recent acquisitions, specifically Bergen Brunswig Medical and Automatic Liquid Packaging (ALP).
- Monitor the customer concentration risk, particularly the reliance on the top two customers for 26% of operating revenue.
- Confirm the company's ability to manage working capital requirements given the significant increase in inventory ($926 million increase) and receivables.